Ablynx and Centocor to research antibody fragments
Executive Summary
Ablynx (antibody discovery and development) and Johnson & Johnson's immunology subsidiary, Centocor Research and Development, agreed to research the administration and delivery of Ablynx's Nanobodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice